Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2021-05-20 Director's Dealing
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-05-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on clinical trial results and other significant events related to Allogene Therapeutics, Inc., including detailed data from Phase 1 trials and safety analyses. It does not contain comprehensive annual or quarterly financial statements or detailed management discussion and analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The document is lengthy (15,000 characters) and contains substantive information about clinical trial results and other events, which fits the purpose of a current report (8-K). Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-05-19 English
PRIMARY DOCUMENT
Director's Dealing
2021-05-17 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the quarter ended March 31, 2021. The document states that the financial results are provided in an attached press release (Exhibit 99.1) and that the information is being furnished, not filed, indicating this is an announcement rather than the full financial report itself. The document length is 3860 characters, which is relatively short and consistent with a report publication or announcement rather than a full interim or quarterly report. According to the rules, if a document is short and states that a report or press release is attached or incorporated by reference, it should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS).
2021-05-05 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a 'Schedule 14A' proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is not a full annual report, earnings release, or other financial report but rather a solicitation document for shareholder voting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short and does not contain financial data or management discussion, confirming it is not a report but proxy materials.
2021-04-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.